Nemes Rush Group LLC Buys 332 Shares of Cigna Group $CI

Nemes Rush Group LLC increased its position in Cigna Group (NYSE:CI) by 8.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,106 shares of the health services provider’s stock after buying an additional 332 shares during the quarter. Nemes Rush Group LLC’s holdings in Cigna Group were worth $1,357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in CI. Mufg Securities Americas Inc. increased its position in shares of Cigna Group by 22.2% in the second quarter. Mufg Securities Americas Inc. now owns 5,920 shares of the health services provider’s stock valued at $1,957,000 after acquiring an additional 1,074 shares during the period. Journey Strategic Wealth LLC grew its stake in shares of Cigna Group by 164.1% in the second quarter. Journey Strategic Wealth LLC now owns 1,949 shares of the health services provider’s stock worth $644,000 after purchasing an additional 1,211 shares during the last quarter. Mediolanum International Funds Ltd increased its holdings in Cigna Group by 60.8% during the 2nd quarter. Mediolanum International Funds Ltd now owns 48,958 shares of the health services provider’s stock valued at $15,975,000 after purchasing an additional 18,509 shares during the period. Brandywine Global Investment Management LLC raised its position in Cigna Group by 5.2% during the 2nd quarter. Brandywine Global Investment Management LLC now owns 174,534 shares of the health services provider’s stock valued at $57,697,000 after purchasing an additional 8,592 shares during the last quarter. Finally, MAI Capital Management raised its position in Cigna Group by 1.6% during the 2nd quarter. MAI Capital Management now owns 9,264 shares of the health services provider’s stock valued at $3,062,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on CI. The Goldman Sachs Group reduced their target price on Cigna Group from $370.00 to $330.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Zacks Research downgraded shares of Cigna Group from a “hold” rating to a “strong sell” rating in a research report on Monday, November 3rd. Barclays dropped their target price on shares of Cigna Group from $383.00 to $300.00 and set an “overweight” rating for the company in a research report on Friday, October 31st. JPMorgan Chase & Co. reduced their price target on shares of Cigna Group from $428.00 to $375.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 4th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Cigna Group from $415.00 to $301.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Cigna Group has an average rating of “Moderate Buy” and an average target price of $334.05.

Cigna Group Trading Up 3.2%

NYSE:CI opened at $278.12 on Friday. The firm has a market capitalization of $74.29 billion, a P/E ratio of 15.18, a PEG ratio of 0.88 and a beta of 0.44. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.71 and a quick ratio of 0.71. Cigna Group has a one year low of $239.51 and a one year high of $350.00. The company’s 50-day simple moving average is $286.74 and its 200 day simple moving average is $298.94.

Cigna Group (NYSE:CI) last announced its earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating analysts’ consensus estimates of $7.64 by $0.19. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The business had revenue of $69.57 billion during the quarter, compared to the consensus estimate of $66.40 billion. During the same quarter last year, the firm earned $7.51 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. As a group, analysts forecast that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, December 4th will be issued a $1.51 dividend. This represents a $6.04 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s payout ratio is 26.64%.

Insiders Place Their Bets

In related news, insider Brian C. Evanko sold 5,368 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the sale, the insider directly owned 51,182 shares of the company’s stock, valued at approximately $15,354,600. This represents a 9.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David Cordani bought 4,134 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average cost of $241.88 per share, with a total value of $999,931.92. Following the completion of the acquisition, the chief executive officer directly owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. The trade was a 2.69% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.70% of the company’s stock.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.